View all veterinary jobs
Conducted as a multicentric international study involving board-certified veterinary dermatologists, the trial included 35 dogs with CIF in at least two paws.
Each dog acted as its own control, and was treated with systemic antibiotics, with one paw being treated with FLE and the other paw without.
Paws were allocated based on a coin toss, and the study was single blinded: the principal investigator was responsible for the assessment of lesions, and the co-investigator was responsible for administration of FLE treatment.
The dogs were assessed over an 8-week period with check-ups every 14 days.
At every check-up the paws treated with FLE showed a greater improvement than paws without FLE treatment.
The lesions were assessed and scored with the global lesion score, the pruritic visual analogue scale, a cytological scoring, and photographic documentation.
The results of the study demonstrated that FLE combined with systemic antibiotics significantly reduced the time to clinical resolution compared to antibiotics alone.
By week four, 50% of paws in the FLE group had reached clinical resolution compared to 17% in the control group.
By week eight, 88% of paws in the FLE group had healed compared to 54% in the control group.
Dr Anja Lange, DVM, Department of Dermatology, AniCura Kleintierspezialisten Augsburg GmbH, Augsburg, Germany, said: “Canine interdigital furunculosis is a challenging condition to treat that can be prolonged and frustrating.
"Having FLE as an additional management tool is very exciting, not least because it speeds up time to healing, but it also requires us to use less antibiotics.
"The use of FLE was well accepted by all of the dog owners from the study and the dogs themselves tolerated it well, showing it can be a very useful adjunct to cases in clinical practice.”
Reference
Phovia is a two-part FLE system consisting of a chromophore gel that is applied to the affected skin and a blue light LED lamp.
When used together they produce light of varying wavelengths that penetrates the skin to different depths, which Vetoquinol says helps to control bacteria and reduce inflammation on the surface of the skin and stimulates regeneration in the epidermal and dermal layers.
The unit is portable, and applications take four minutes once a week.
After diagnosis and subsequent recommendation by a veterinary surgeon, any trained member of the clinical team can use Phovia.
For the study, which was led by Dr. Andrea Marchegiani, nine female dogs that had undergone unilateral or bilateral mastectomy for mammary neoplasia had half their wounds treated with FLE, whilst the other half served as the control and received no FLE.
To assess the potential benefits of FLE in reducing infection risk, swabs were taken for culture and sensitivity three, five and seven days after surgery.
The swabs from all FLE-managed wound portions showed no bacterial growth, in contrast to the control wounds, in which three dogs had positive culture results.
Andrea said: “For many reasons healing of surgical wounds can become challenging, especially after removal of mammary gland lumps.
"Veterinary clinicians have to face the three-fold challenge of meeting owner expectations of prompt and trouble-free wound healing, recognising those wounds in which healing may be prolonged or impaired and also following the principles of antibiotic stewardship.”
The study concluded that the research underscores the value of Phovia as a significant adjunct to conventional postoperative care in veterinary medicine, offering the dual benefits of reducing potential infection risks and lessening the home care burden for pet owners.
FLE’s application could potentially replace certain topical treatments and improve overall compliance by simplifying the administration of home therapies, thereby relieving pet owners of some responsibilities associated with postoperative care.
https://www.mdpi.com/2076-2615/14/8/1250
Phovia, which was launched in the UK last year, is a two-part FLE system consisting of a chromophore gel that is applied to the affected skin and a blue light LED lamp.
Vetoquinol says that when used together they produce light of varying wavelengths that penetrates the skin to different depths, helping to control bacteria and reduce inflammation on the surface of the skin and stimulating regeneration in the epidermal and dermal layers.
The authors of the Vetoquinol-funded study say that FLE has already been shown to support and accelerate natural skin healing, but this latest research shows that the benefits go beyond improvement in clinical signs.
The study looked at 35 dogs with a diverse range of skin conditions: 13 had interdigital furunculosis, 10 had deep pyoderma, 6 had wounds, 4 had pyotraumatic dermatitis, and 2 had perianal fistula on presentation.
Eight of 35 dogs were new cases, whereas the remaining 27 were undergoing recrudescence of a prior episode, including pyotraumatic dermatitis, wounds, deep pyoderma, interdigital furunculosis and perianal fistulae.
Thirty dogs (86%) achieved a clinical resolution: 18 with the Fluorescent Light Energy alone and 12 with the concomitant use of FLE and topical antiseptic shampoo.
Five dogs (14%) had a partial response and needed other therapies.
92% percent of owners attested to their pet’s enhanced quality of life, with 74% of dogs displaying at least a 50% improvement in owner-reported behaviour, mood, sleep and playing activities.
The study also reported a 46% reduction in caregiver burden.
Felicity Caddick, Technical Services Manager at Vetoquinol said: “Managing skin conditions often requires the long-term use of shampoos or topical therapies.
"Many owners find this aspect of pet ownership challenging, especially with larger dogs, or less cooperative animals.
"FLE can reduce or in some cases eliminate the need for topical therapies at home, not only simplifying the treatment process but also enhancing convenience and compliance.
"Sharing responsibility for administering ongoing treatment with their vet practice also removes some of the worry associated with their pet’s health.”
Vetoquinol also highlights that Phovia can offer vets a drug-free management option for skin disorders that aligns with the principles of antibiotic stewardship.
Felpreva contains emodepside and praziquantel, with tigolaner, a novel bispyrazole active ingredient.
Felpreva is licensed for treatment of cats with, or at risk from, mixed parasitic infestations/infections.
Vetoquinol points to a survey revealed conducted last year in which 43% of cat owners said that giving parasite protection to their cat makes them feel guilty, stressed, or worried1.
Felpreva provides an option to reduce the frequency of treatments, lessening stressful interactions between owners and their cats.
Vetoquinol says that with Felpreva’s convenience and longer-lasting flea and tick protection, it aims to help support compliance and thus improve the wellbeing of feline companions.
Helen Hunter, Senior Product Manager at Vetoquinol UK, said: “The launch of Felpreva is a truly proud moment for Vetoquinol, demonstrating our expertise, passion, and commitment to innovation in this essential category of companion animal medicine.
"It will allow us to safeguard the health of cats by bringing longer-lasting protection, convenience, and ease of use – for both pet owners and veterinary professionals.
"At a time when vets are treating more pets than ever before, the need for a breakthrough endectocide solution like Felpreva has never been greater.”
Felpreva is in wholesalers now.
For more information, contact your local Vetoquinol representative.
Felpreva is the first spot-on parasiticide for cats that covers tapeworms in addition to other endoparasites including gastrointestinal roundworms and lungworms, and ectoparasites (fleas, ticks and mites) for up to three months with a single dose.
It is licensed for treatment of cats with, or at risk from, mixed parasitic infestations/infections, including:
Matthieu Frechin, Vetoquinol CEO, said: “Marketing authorisation is a pivotal achievement for both Vetoquinol and Felpreva.
"It is a breakthrough treatment with convenience and simplicity of use combined with long-lasting efficacy.
"We believe that Felpreva will be a real game changer for this area of veterinary medicine, demonstrating our commitment to the parasiticide market.”
It is anticipated that Felpreva will be available in Europe early in 2022.
The company initiated the recall after identifying a potential for the sterility/stability of the product to be compromised due to a crimping problem of the aluminium cap.
The recall is for the 100 ml bottles of the following batch only:
Batch No.0C3829 Expiry Date 03/12/2022
Vetoquinol UK Ltd is contacting veterinary surgeons and veterinary wholesalers to examine inventory immediately and quarantine products subject to this recall.
For further information, contact the Customer Services Department on +44 1280 814500 Option 1 or email: UK_office@vetoquinol.com.
The company says the return to a ‘new normal’ post-lockdown provides a significant opportunity for practices to apply a renewed focus to preventative healthcare, recommending parasiticides as a way to improve animal welfare and generate practice revenue, which is vital for economic recovery.
Caitrina Oakes, Vetoquinol Managing Director UK and Ireland, said: “With many pet owners spending more hours than ever with their pets during lockdown, companion animal parasiticides have never been more important – making Profender and Drontal highly relevant in the current environment.”
She added: “It’s a very challenging time for many veterinary practices as everyone adapts to the post-COVID world. I’m looking forward to seeing how the passion and ambition we bring to our brands helps Profender and Drontal to grow and helps us to better serve the needs of the veterinary community, both now and in the future.”
Up to date information on the brands and their distribution can be found on the Vetoquinol website, www.vetoquinol.co.uk, by calling 01280 814500, or practices can contact their Vetoquinol Territory Manager directly.
The company points to research which shows that most dogs and cats whose congestive heart failure is well controlled by medication will have a stable sleeping respiratory rate of less than 30 breaths per minute1,2.
Vetoquinol says SRR is a sensitive indicator of pulmonary oedema or pulmonary effusion which can occur as heart failure patients deteriorate, and that monitoring of SRR is a useful biomarker for veterinary surgeons, allowing you to track progression of congestive heart failure and to detect stability during treatment.
The company also says SRR is most easily detected by the owner when the pet is asleep: using the app to count and record SRR gives clients a good indication of when to seek veterinary intervention and generates data that helps veterinary teams seeking to minimise unnecessary face-to-face contact but still provide emergency care.
While an SRR in the reference range does not exclude heart disease, it reduces the probability that the patient is suffering from left sided heart failure, so may also be a useful measure for remote triage as part of a wider assessment. Other causes of elevated SRR include pain, pneumonia, stress and heatstroke.
Helen Hunter, Product Manager at Vetoquinol and part of the team that developed the app said: "Being able to monitor patients with congestive heart failure is important at any time but during lockdown, with some routine checks having to be postponed, having a means of remote monitoring is more important than ever.
"This tool will help veterinary professionals make the judgement call about whether the pet needs to be seen, especially when the results are provided in the context of monitoring that has taken place over time, providing an assessment of what is normal for that patient."
To complement the addition of the new tool, the site has also launched a webinar delivered by RCVS Recognised Specialist in Cardiology, Dave Dickson of Heart Vets. The presentation discusses the ‘10 Golden Rules of Congestive Heart Failure' and covers topics including the importance of clear radiography and why a cough is not diagnostic of CHF.
Dave said: "Sleeping respiratory rate is one of the most useful ways to monitor an animal in CHF or to look for signs of CHF developing. By encouraging pet owners to monitor and track the dog's sleeping respiratory rate at home, owners can provide vets with a valuable insight into the success of the current treatment regime. The UpLife app is free and will be really helpful to vets and pet owners, both now during lockdown and in the future."
The app can be accessed at www.uplife.uk/srr and it can be communicated to clients at the point when their pet is diagnosed, or shared with clients whose pets already have a diagnosis and are under treatment.
For further information, contact your Vetoquinol Territory Manager, email uk_marketing@vetoquinol.com, or call 01280 814500.
References
The deal is expected to complete by the middle of 2020.
According to the terms of the deal, Vetoquinol will acquire the Profender and Drontal product families, the intellectual property, registrations and other rights currently owned by Bayer AG’s animal health business.
Jeff Simmons, president and CEO of Elanco said: "We’re pleased with the continued progress on a number of fronts to move the acquisition of Bayer AG’s animal health business toward completion.
Matthieu Frechin, CEO of Vetoquinol, said: "We are very pleased to acquire the Profender and Drontal product lines that are highly valued by veterinarians and pet owners. The acquisition of these two strong brands is at the heart of our strategy. On the one hand, they will significantly increase the size of our business and our visibility in the parasiticide segment, one of our strategic therapeutic areas. On the other hand, they will strengthen our portfolio of Essentials, the engine of our growth."
Vétoquinol, the maker of Zylkène, has announced that Nicola Jamieson, an RVN at Ardene House Vets in Aberdeen, has won the company's £5,000 bursary to help a veterinary nurse extend their knowledge of animal behaviour and further their career.
The bursary covers a year of the Centre of Applied Pet Ethnology (COAPE) Behaviour Diploma, which is designed to give professionals the skills to deal with situations that may arise during the course of their work.
Applicants were asked to demonstrate their interest in the subject of companion animal behaviour and explain how they felt the bursary would help them achieve their career ambitions.
Krystyna Joyce, Product Manager at Vétoquinol said: "The standard of applications was incredibly high and it was fantastic to see so many veterinary nurses keen to further their knowledge and learn more about the field of companion animal behaviour. Nicola's dedication, passion and experience really stood out and we're delighted to be able to help Nicola to take this next step in her career."
Nicola said: "I have always been interested in animal behaviour and since registering as a veterinary nurse I have been eager to expand my knowledge in order to support both pets and owners. Behaviour is something that is brought up daily and in my opinion COAPE is leading the way in the provision of behaviour education, so I'm really excited to have the chance to study with them."
Vétoquinol, manufacturer of Epiphen (phenobarbital), for the control of epilepsy in dogs, has announced the launch of a new starter pack for clients that are embarking on treatment.
The starter packs contain a variety of support materials designed to help owners better understand the condition and its treatment. They sit alongside other support given by the company, which includes an 'Ask the Expert' helpline through which Epiphen veterinary customers can speak to a neurology specialist at The Animal Health Trust in Newmarket, where Vetoquinol sponsors a neurology clinician.
Abbie King, Product Manager for Epiphen, said: ''Our 'Ask the Expert' helpline is a successful service that has been running for several years. 30% of the calls to Vetoquinol's technical team relate to this challenging condition meaning there are few queries our technical team have not tackled before. If extra help is necessary we have an excellent working relationship with The Animal Health Trust and regularly refer cases to them for further advice. We are very proud of this service and are delighted to be able to continue to provide this helpline for our Epiphen clients.''
To use the 'Ask the Expert' service, or order the support materials, ring 0800 1698197. Alternatively visit: www.vetoquinol.co.uk or www.epiphenonline.co.uk.
Vetoquinol - makers of the NSAID Cimalgex - has announced the launch of its updated website www.CiMyDog.co.uk.
The company says the website has been developed to provide reliable online information about pain in dogs to cater for the increasing needs of pet owners and vets.
The website has two sections. The first is a pet owner focussed, educational tool which takes the visitor on a journey through the process of pain; from spotting the signs of pain all the way through to ways of relieving pain, culminating in the recommendation that the visitor seeks advice from their veterinary practice.
The second section requires registration as it contains more in depth information on the pain process and potential treatment options available, this section is for veterinary professionals only. Also on this section of the website there are many scientific abstracts related to pain and treatment with links to enable the veterinary visitor can view this peer reviewed material.
Robert Simpson, Cimalgex Product Manager said: "The internet is a very powerful tool in terms of increasing education, especially in areas such as canine pain. Unfortunately there can also be a lot of misinformation online and so we felt it was important for Vetoquinol to try and redress the balance by producing www.CiMyDog.co.uk. This can be used as a reliable and up-to-date resource by pet owners and veterinary professionals alike. -
www.CiMyDog.co.uk is a very interactive site which aims to demystify the pain treatment process, ensure pet owners look out for behavioural signs of pain and looks to improve overall canine health with assistance from their veterinary practice. We hope that this will be a valuable resource to which vets can refer their pet owners."
Rimifin (carprofen), an NSAID marketed by Vetoquinol, has been given a new flavour to help increase compliance.
Robert Simpson, Product Manager for Rimifin said: "Pet owner compliance and involvement in chronic pain situations is critical to ensuring effective long term treatment. Ease of administration is also very important in this setting. The addition of this flavouring to this popular and cost effective NSAID will help to ensure that administration to the patient is as easy as possible for pet owners and vets."
To find out more about Rimifin please contact your Vetoquinol Territory Manager or call 01280 825424.
Vetoquinol, makers of Sedalin (acepromazine), has published a free clipping guide for horse owners.
The company says the launch of the guide has been timed to coincide with the horse clipping season, when owners may be considering sedating horses to make things safer for themselves and their horses.
The guide refers owners to their veterinary surgeon for professional advice if sedation is appropriate.
The company has also produced promotional practice posters: ' Less Stress more Success'
For your poster and accompanying guides, contact your Vetoquinol Territory Manager or Teleservices directly on 01280 825424. You may also wish to put a link to a downloadable version of the guide on your practice website: http://www.vetoquinol.co.uk/clippingguide.pdf
Vetoquinol has announced the launch of Chrysanphyton, the latest addition to its range of Equistro feeding stuffs for horses.
Vetoquinol says Chrysanphyton is recommended for horses where support of a normal blood flow to the hoof is important. It contains Chrysantellum americanum, blackcurrant and hazelnut extracts which, according to the company, provide a rich source of nutrient bioflavanoids and vitamins.
The recommended administration of Chrysanphyton is 10ml twice a day in horses (500kg) and 5ml twice a day in ponies with the 1000ml pack lasting 50 or 100 days respectively.
A product information sheet is available on the Equistro website www.equistro.co.uk
For further information contact your local Vétoquinol Territory Manager.
Vetoquinol has published a waiting room poster which highlights canine pain, to support Cimalgex.
Robert Simpson, Product Manager for Cimalgex said: "This poster aims to highlight that pain may not be obvious to pet owners and that signs which the owner may believe to be age related, for example stiffness, may actually be behavioural signs of pain. The most common sign of pain is a change in behaviour and so this is an area which we believe needs to be highlighted to the pet owner1.
"This new poster uses a strong image to catch the pet owner's attention which, when combined with its simple message, will prompt the pet owner to ask for further information from the veterinary practice regarding pain to ensure the overall wellbeing of their pet. This poster complements our client leaflet in helping the veterinary practice to assist the pet owner to spot signs of pain which may not be very obvious."
To find out more or to request a waiting room poster for your practice please contact your Vetoquinol Territory Manager or call 01280 825424.
1. Hellyer P. et al. AAHA/AAFP Pain Management guidelines for Dogs and Cats. J. AM Anim Hosp Assoc 2007; 43: 235-248.
Vetoquinol UK Ltd has launched a new flea and tick treatment for cats and dogs.
Flevox is a spot-on solution containing fipronil and comes in unique pack sizes of either single pipettes or large clinic packs of 36.
Product Manager Helen Walker said: "With only 55% of pet owners buying their flea and tick treatment from the vet, we recognise there is a huge opportunity to develop and grow this essential market. In the modern age the consumer expects maximum flexibility, and that is what we aim to provide with Flevox.
Whether it be persuading the price-conscious customer away from buying their flea treatments in supermarkets and the internet, or encouraging those who don't treat their pet at all to give it a try without breaking the bank, we're confident we can help grow flea treatment sales in practice."
Vetoquinol says it is supporting the new product with a range of materials dedicated to veterinary surgeries, providing incentives to encourage client bonding and repeat business with your practice.
Helen continued: "We have also teamed up with the fantastic charity Dogs for the Disabled by making a donation for every pipette of Flevox sold. We're really looking forward to raising the profile of this organisation where these amazing dogs give life changing independence to disabled people. We're confident the donation will strike a chord with clients and really engage them with the charity, the Flevox brand and the practice".
To find out more, contact your Vetoquinol territory manager or visit http://www.vetoquinol.co.uk/
Vetoquinol has launched Myo Power, the latest addition to the Equistro Performance range of nutritional supplements.
The company says that Myo Power has been formulated with the performance and convalescent horse in mind, and that it is an excellent source of easily digestible protein enriched with L-Leucine and other key essential amino acids necessary for optimal muscular cell development, specifically via the mitochondria.
Vetoquinol claims the product is extremely beneficial for young horses being prepared for sales, competition horses in training, and the convalescent or older horse following periods of box rest or restricted exercise.
Myo Power is available in 1.2kg and 2.3kg tubs. For further information, please contact your local Vétoquinol Territory Manager.
Vetoquinol has announced that the 50g pack size of Ipakitine will shortly be replaced by a 60g pot.
The company says this will provide the convenience of a 30 day supply for a 5kg cat or dog who is on 1g/5kg bodyweight twice a day (one level scoop twice a day).
The 60g pot will be available from the end of December. Also at this time, the existing 150g size pot will be replaced by a 180g pot.
The new packaging is more eye-catching, easier to read and gives more description. A 300g pot will also be available in February 2012. Pricing will be in-line with increase in pack size, so proportionally a 20% increase for 20% more product.
Ipakitine is a phosphate binder formulated specifically for veterinary use. It is designed for both cats and dogs and is available as a tasteless powder formulation for easy administration with food.
Vetoquinol has announced the launch of Equistro Flexadin UCII, an equine joint supplement.
Equistro Flexadin UCII contains a new ingredient, UC-II, which the company claims is one of the most effective and influential ingredients available that aids and supports healthy joint function.
To celebrate the launch of Flexadin UCII Vetoquinol is offering a £10 money off voucher available through purchases of Horse & Hound magazine starting from November 10th.
Caitríona Mullin, Equine Product Manager at Vetoquinol UK Ltd said: "We are very excited about the launch of Flexadin UCII in the UK and Ireland, we have already received excellent feedback from our German and French colleagues. Flexadin UCII is a product that will further enhance our premium range of equine supplements formulated specifically for the performance horse."
Vetoquinol is launching Cimalgex, a new NSAID for dogs this month.
Cimalgex (cimicoxib) is a new second generation COX-2 inhibitor which can be used for the treatment of pain and inflammation due to osteoarthritis and the management of peri-operative pain associated with orthopaedic and soft tissue surgery, for which it can be given two hours before surgery and continued for 3-7 days post surgery.
Vetoquinol says that an important consideration in treating dogs with osteoarthritis, many of which are geriatric, is that there are no contraindications to using Cimalgex in patients with mild to moderate renal impairment.
According to the company, field trials showed that over 90 per cent of per owners and vets identified that animals experienced excellent analgesia post operatively*.
Available in a chewable, splitable tablet, Cimalgex can be given with or without food.
Vetoquinol says that the excellent tolerability, efficacy profile and ease of use of Cimalgex means that veterinary patients could benefit from pain relief in situations where clinicians are worried about the risks versus the benefits of prescribing a NSAID for pain management.
Further information about assessing pain and decision making when it comes to prescribing NSAIDs, will be presented in a free webinar on 19th October at 8.30pm. To register go to www.thewebinarvet.com/vetoquinol and enter code CIM1.
Reference*E. Grandemange: Field evaluation of the efficacy and the safety of cimicoxib in the relief of peri-operative pain in dogs; 2008, study number n°3008C2F1
Vetoquinol has released the second set of results from a survey of over 1000 dog owners which the company says has revealed some surprising findings on owner attitudes to pain and pain relieving medications.1
In particular, Vetoquinol says it thinks veterinary surgeons will be surprised by the depth of feeling expressed by pet owners about the issue, and that there are areas where there is potential for the profession to relate to the concerns of clients and adapt communication accordingly.
The key findings highlight that dog owners are likely to be shocked by a diagnosis of long term painful illness in their pet and are very likely to search for further information on the Internet about the pet's condition. Most dog owners think that NSAIDs are likely to cause side effects, with the perceived risk being much greater than the actual level of risk. The results also indicate that even low levels of risk of side effects may be unacceptable to dog owners.
Mark Leddy, Marketing Manager at Vétoquinol said that the strength of the bond between pet and owner should always be front of mind: "A diagnosis of osteoarthritis, for instance, is such a common one, often being made several times a day, so it is easy to become matter of fact about it; yet for the client that news may actually be quite traumatic and the impact hugely underestimated."
Where clients get their information from is important:
The majority of respondents (95%) felt that treatment of osteoarthritis should be started as soon as signs appear and then long term, either consistently or as needed. However, despite recognising the need for treatment, many expressed concerns about side effects when giving their dog long-term medication, with 77% considering it important or very important to choose a medication with a limited range of side effects.
Vetoquinol says the reality is that one in a thousand pets given an NSAID is likely to experience side effects, which vets may feel is not something owners should worry about unduly. The reality for pet owners is that they perceive the risk to be much greater and if informed of the actual level of risk may still experience a significant level of fear that their pet, with whom they have a special relationship, could be that one in a thousand.
Mark Leddy says that, based on these results, there is great scope for the veterinary team to discuss the level and type of risk entailed in administering medication: "Such an approach will help pet owners make more informed decisions about treatment, allay their concerns and provide them with the support they need at what is probably a very difficult time for them."
1. A survey of 1048 dog owners, carried out by petbuzz, on behalf of Vétoquinol, March 2011
Vetoquinol has launched www.epiphenonline.co.uk, to support the veterinary profession and dog owners in the management of epilepsy.
The company says it has developed the online service to complement its existing monitoring aids and booklets, and give the best possible support to vets and patients during the complex process of stabilising and managing seizures.
The online service enables owners to keep a seizure diary, and share it with their veterinary surgeon so that they can prescribe an appropriate medication and management programme.
According to Vetoquinol, approximately three to five per cent of dogs suffer from idiopathic epilepsy, (which accounts for 80 per cent of epileptic seizures). The condition is inherited in some breeds, including Beagles, Dachunds, Keeshonden, German Shepherds and Belgian Tervurens.
Documenting the animal's history and seizure activity is crucial in assessing the progression of epilepsy. It also provides invaluable information for diagnosis and maintenance of effective therapeutic control.
Vetoquinol has launched the Vet-Touch Digital Atlas, an innovative communication tool to help veterinary practices explain complex conditions to clients at the touch of a screen.
Vetoquinol says the Vet-Touch Digital Atlas saves valuable time and will allow you to offer an improved service to your clients, by maximising their comprehension of the case.
The Vet-Touch Digital Atlas has a 15 inch (38cm) touch screen monitor and comes with a range of animated movies. It's available to buy from your Vetoquinol Territory Manager.
For further information visit http://www.vetoquinol.co.uk/ or contact Vetoquinol on 01280 825 424.
Vetoquinol has revamped its Epiphen complimentary voucher scheme for testing serum levels of phenobarbital, and is offering vet practices a chance to win £100 of high street vouchers.
New voucher pads will be posted to participating veterinary practices in August. The re-vamped scheme also includes freepost envelopes to make the free serum monitoring programme more user-friendly.
Practices are being asked to send back the old vouchers, which can be found in both the 30mg and 60mg Epiphen packs, to take part in a monthly prize draw to win £100 of high street vouchers. To enter, return the vouchers with the practice name on the back of each voucher. There will also be a quarterly prize draw for a "Touch Screen" client education tool.
The old vouchers should be sent to: Voucher Amnesty, Vetoquinol, Vetoquinol House, Great Slade, Buckingham Industrial Park, Buckingham, MK18 1PA.